Updated results from the phase 3 helios study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma

HIGHLIGHTS

• who: G. Fraser from the (UNIVERSITY) have published the paper: Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma, in the Journal: (JOURNAL) of September/19,/2012
• what: The authors report follow-up results from the randomized placebo-controlled phase HELIOS trial of ibrutinib+bendamustine and rituximab (BR) for previously treated (CLL)/small lymphoma (SLL) without deletion 17p. The authors report updated data from HELIOS (3-year follow-up) to determine survival outcomes, evolution of responses, and durability of remissions across patient subgroups . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.